drugset / Trial / NCT06874946
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
Phase 1/2
Recruiting
30 enrolled
Peking University People's Hospital
Hebei Senlang Biotechnology Inc., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
Timeline
- Start
- 2025-02-14
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD5-targeted CAR-T cells | Cell therapy | 0.5 cells/kg | — |
| Subject | CD5-targeted CAR-T cells | Cell therapy | 1 cells/kg | — |
| Subject | CD5-targeted CAR-T cells | Cell therapy | 2 cells/kg | — |